The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.
|Number of pages||12|
|Journal||Advances in Therapy|
|Publication status||Published - 1995|
- chronic obstructive pulmonary disease
ASJC Scopus subject areas